港股创新药ETF(513120)早盘冲高涨近2%，近5日累计“吸金”3.54亿元

Group 1 - The Hong Kong Innovation Drug ETF (513120) has shown strong performance, with a recent increase of 1.90% and a total scale reaching 15.257 billion [1] - The ETF has attracted significant capital inflow, accumulating 354 million over the last five trading days, and has a one-year net value increase of 127.14% [1][2] - The index tracks up to 50 listed companies involved in innovative drug research, with a high concentration in biopharmaceuticals and chemical pharmaceuticals, accounting for 92.5% of the index [2] Group 2 - The top ten weighted stocks in the index account for 70.59%, including companies like 康方生物 (09926) and 信达生物 (01801) [2] - The innovation drug sector is entering a phase of "clinical value reassessment," shifting from a narrative-driven valuation to a profit-driven approach, indicating long-term investment potential [2] - The sector is expected to maintain its growth due to policy support, enhanced global competitiveness, and successful commercialization [3] Group 3 - The ETF allows T+0 trading, enhancing liquidity and efficiency for investors [3]